BackMerrimack Pharmaceuticals Overview

Merrimack Pharmaceuticals Other Current Assets

Latest other current assets for MACK: $210K.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$209000.00
7.93% YoYΔ $-18000.00 vs prior year quarter

Peer average

Loading

Merrimack Pharmaceuticals Other Current Assets History

Loading

Merrimack Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Merrimack Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Merrimack Pharmaceuticals (MACK) FAQ

Merrimack Pharmaceuticals (MACK) currently reports a other current assets of $210K as of March 2024. That compares with $230K in the prior-year period — down 7.9% year over year. Use the charts on this page to explore Merrimack Pharmaceuticals's other current assets history and peer comparisons.

Merrimack Pharmaceuticals's other current assets decreased from $230K to $210K — a 7.9% year-over-year decrease (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Merrimack Pharmaceuticals reported $210K in other current assets as of March 2024. That compares with $230K in the prior-year period — down 7.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $210K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Merrimack Pharmaceuticals, and consider following MACK for alerts when major investors trade the stock.

Merrimack Pharmaceuticals is classified in the Healthcare sector. On other current assets, it currently shows $210K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MACK with unrelated industries.